一分钟看懂
这是一项关于前列腺癌的III 期研究，登记的药物或干预包括PF-06821497；Placebo；Enzalutamide，当前状态为招募中。登记地点显示中国芜湖、北京、福州、广州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
PF-06821497；Placebo；Enzalutamide · III 期
登记条件中文摘要
登记的基本范围为男性，年龄18 岁；另列出4项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Wannan Medical College Yijishan Hospital · 芜湖
- Cancer Hospital Chinese Academy of Medical Science · 北京
- Fujian Cancer Hospital · 福州
- Guangzhou First People's Hospital · 广州
- The Second Affiliated Hospital of Shantou University School of Medicine · 汕头
- The Second Affiliated Hospital of Guilin Medical University · 桂林
- The Third Affiliated Hospital of Xinxiang Medical University · 新乡
- Henan Cancer Hospital · 郑州
- Union Hospital Tongji Medical College Huazhong University of Science and Technology · 武汉
- Hunan Cancer Hospital · 长沙
- Inner Mongolia People's Hospital · 呼和浩特
- Huai'an First People's Hospital · 淮安
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School · 南京
- Nantong Tumor Hospital · 南通
- The Second Affiliated Hospital of Soochow University · 苏州
- The First Affiliated Hospital of Xi'an Jiaotong University · 西安
- Shaanxi Provincial People' Hospital · 西安
- Shandong Provincial Hospital · 济南
- The Affiliated Hospital of Qingdao University · 青岛
- Weifang People's Hospital · 潍坊
- Yantai Yuhuangding Hospital · 烟台
- Tongji Hospital of Tongji University · 上海
- West China Hospital, Sichuan University · 成都
- Sir Run Run Shaw Hospital, Zhejiang University School of Medicine · 杭州
- The first affiliated hospital of Ningbo university · 宁波
- The First Affiliated Hospital of Wenzhou Medical University · 温州
- The First Hospital of Jiaxing · 嘉兴
- Peking University Third Hospital · 北京
- First Affiliated Hospital of China Medical University · 沈阳
- The Second Hospital of Tianjin Medical University · 天津
公开的入选条件
- * Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features.
- * Metastatic disease in bone documented on bone scan, or in soft tissue documented on CT/MRI scan.
- * Progressive disease in the setting of medical or surgical castration.
- * ECOG performance status 0 or 1, with a life expectancy of ≥12 months as assessed by the investigator.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06629779；登记信息更新于 2026-09-25。